Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECIDENTD
NCT05390892Phase 4Recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2022
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Total (first and recurrent) cardiovascular, kidney, and death events. Started Sep 2022; status: recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT05390892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05390892.